Drug Trial Radar · NCT07900633
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Nov 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
Conditions
- Obesity
- Overweight
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
Interventions
EloralintideDrug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: Baseline, Week 64
- Change from Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline, Week 36
Locations
308 sites in 21 countries. Site status is shown where the registry gives one.
Central Research Associates
Birmingham, Alabama
University of Alabama - Department of Nutrition Sciences
Birmingham, Alabama
Nephrology Consultants
Huntsville, Alabama
Smiths Medical Center
Apache Junction, Arizona
Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC
Gilbert, Arizona
Elite Clinical Studies, LLC
Phoenix, Arizona
Southwest Kidney Institute, PLC
Sun City, Arizona
Valley Clinical Trials, Inc.
Covina, California
Neighborhood Healthcare Institute of Health
Escondido, California
First Valley Medical Group
Lancaster, California
Ark Clinical Research
Long Beach, California
Valley Clinical Trials, LLC dba Flourish Research
Northridge, California
FOMAT Medical Research
Oxnard, California
Acclaim Clinical Research
San Diego, California
Care Access - Santa Clarita
Santa Clarita, California
Millennium Clinical Trials
Westlake Village, California
Chase Medical Research, LLC
Waterbury, Connecticut
Omega Research Orlando
Altamonte Springs, Florida
Care Access - Brandon - Clinical Trials Center by Walmart & Care Access
Brandon, Florida
American Research Institute
Cutler Bay, Florida
Fleming Island Center for Clinical Research
Fleming Island, Florida
Northeast Research Institute - Downtown Office
Jacksonville, Florida
Lakeview Institute of Clinical Research
Leesburg, Florida
Millennium Medical Research - Miami
Miami, Florida
Onhealth Research Center
Miami, Florida
Center for Diabetes, Obesity, and Metabolism
Pembroke Pines, Florida
Peace River Cardiovascular Center
Port Charlotte, Florida
Southeastern Clinical Research Institute
Augusta, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Care Access - Arlington Heights
Arlington Heights, Illinois
Healthcare Research Network - Chicago
Tinley Park, Illinois
American Health Network of Indiana, LLC - Greenfield
Greenfield, Indiana
Care Access - Baltimore
Baltimore, Maryland
Ascension Saint Agnes Heart Care
Baltimore, Maryland
Lucida Clinical Trials
New Bedford, Massachusetts
Lake Michigan Nephrology
Saint Joseph, Michigan
Revive Research Institute, Inc.
Southfield, Michigan
SKY Integrative Medical Center/SKYCRNG
Ridgeland, Mississippi
Clinvest Headlands Llc
Springfield, Missouri
DaVita Clinical Research - Las Vegas
Las Vegas, Nevada
Showing 40 of 308 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.